BioNTech and Bristol Myers Squibb unveiled the first global data for their PD-L1xVEGF bispecific antibody in combination with chemotherapy for small cell lung cancer. Mid-stage results demonstrated encouraging anti-tumor activity, consistent with earlier findings from China. These findings support continued development and upcoming Phase 3 studies in this hard-to-treat cancer subtype. The drug aims to capitalize on dual immune checkpoint and angiogenesis inhibition, a promising strategy in oncology.